Management of Progressive MS Without Relapses
For patients with progressive MS showing slow disability worsening but no clinical relapses, obtain brain MRI with and without gadolinium contrast to detect subclinical inflammatory activity, as this determines whether disease-modifying therapy will be beneficial. 1
Diagnostic Approach
The critical first step is distinguishing between inflammatory-driven progression (which may respond to therapy) versus purely neurodegenerative progression (which has limited treatment options):
MRI Evaluation
- Brain MRI with gadolinium contrast is essential even without relapses, as subclinical disease activity occurs much more frequently than clinically apparent relapses 1
- Gadolinium enhancement indicates active blood-brain barrier breakdown and ongoing inflammation 1
- Look for:
- New or enlarging T2 lesions
- Gadolinium-enhancing lesions (indicating active inflammation)
- Brain and spinal cord atrophy progression 1
Add Spinal Cord Imaging When:
- Brain MRI is nondiagnostic but disability is worsening 1
- Symptoms suggest spinal cord involvement 1
- Use cervical and thoracic spine MRI with and without contrast 1
Treatment Decision Algorithm
If MRI Shows Active Disease (enhancing lesions or new T2 lesions):
- Consider disease-modifying therapy - the patient has inflammatory activity that may respond to treatment
- Higher-efficacy therapies targeting B-cells (ocrelizumab, ofatumumab) or BTK inhibitors show promise for progressive disease with inflammation 2
- Repeat MRI in 6 months to assess treatment response 1
If MRI Shows No Active Disease:
- Current disease-modifying therapies provide limited benefit in progressive MS without inflammatory activity 3, 4
- The evidence shows people with slowly worsening progressive MS may not experience benefit from approved MS therapies in the absence of active disease (relapses or new MRI lesions) 3
- Focus shifts to symptomatic management and rehabilitation 5, 6
Critical Distinction: Primary vs Secondary Progressive MS
The pattern of gadolinium enhancement differs significantly:
- Secondary progressive MS: ~80% of new lesions show enhancement 7
- Primary progressive MS: Only ~5% of new lesions enhance 7
This explains why primary progressive MS has historically been so difficult to treat - there is minimal inflammatory activity to target.
Monitoring Strategy
With Inflammatory Activity:
- Follow-up brain MRI every 6 months to 2 years, particularly when unexpected clinical worsening occurs 1
- If MRI shows disease activity without clinical symptoms, repeat MRI without gadolinium in 6 months 1
Without Inflammatory Activity:
- Shift to palliative care approach for severe progressive disease 8
- Focus on multidisciplinary symptom management: spasticity, fatigue, bladder dysfunction, pain, cognitive deficits, depression 5, 6
- Consider home-based palliative care services 8
Common Pitfall to Avoid
Do not assume absence of relapses means absence of disease activity. Brain and spinal cord atrophy may progress even when treatments suppress gadolinium-enhancing lesions 1. The key is identifying whether any residual inflammatory component exists that could be therapeutically targeted, versus purely neurodegenerative progression where current therapies offer minimal benefit.